More than 4 years after his acquired brain injury and stroke, a son and his mother travel from Melbourne, Australia to TransBarrier® in Boca Raton, Florida for treatment.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

From Melbourne, Australia to TransBarrier® Los Angeles in February 2015. Wonderful to watch!

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Pain after stroke represents an enormous unmet medical need for those who do not adequately respond to conventional treatment. Chronic central post-stroke pain affects countless stroke survivors around the world. This video depicts the presence of chronic central post-stroke pain prior to treatment at TransBarrier® in Boca Raton. Included is a demonstration of allodynia, i.e. pain or discomfort produced by a sensory stimulus, in this case cold, that normally would not provoke discomfort. In many individuals with central post-stroke pain sensory stimuli, such as light touch, that would normally not be noxious, produce extreme discomfort. Some individuals are unable to tolerate normal touch or even showering because of this post-stroke pain condition. This video depicts the rapid response to a single treatment dose administered on May 7, 2015 at the TransBarrier®.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2014 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

From NSW in Australia to TransBarrier® in Los Angeles, June 2015. Wonderful and amazing to see rapid improvement in vision, within minutes.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From the Gold Coast, Australia to TransBarrier® Los Angeles, June 2015. What a wonderful attitude and lovely improvement! The final portion of the video depicts the patient speaking with two of the physicians of TransBarrier® Physicians in Los Angeles, describing his sustained improvement through one week.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From Maine to TransBarrier® in Boca Raton, Florida, July 2015.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

From Brazil to TransBarrier® in Boca Raton, Florida, in July 2015, 3.5 years after a severe stroke caused intractable chronic quadriparesis.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

Immediate improvement in post-stroke aphasia (naming of family members) and restoration of ability to run within minutes of treatment at TransBarrier® in Boca Raton, July 2015, two years after stroke. Sons and wife comment on his rapid and remarkable therapeutic response.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Rapid clinical improvement 10 years after brain injury following treatment at TransBarrier®in Boca Raton, Florida. The patient and her parents flew from Australia to TransBarrier® to receive treatment.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Please see transbarrier.com for more detailed information. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.